학술논문
Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung
Document Type
Article
Author
Source
In: Kaohsiung Journal of Medical Sciences . (Kaohsiung Journal of Medical Sciences, May 2024, 40(5):467-476)
Subject
Language
English
ISSN
24108650
1607551X
1607551X